Navigation Links
Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
Date:1/9/2008

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Faes Farma (Spain) on its recently-completed commercial partnering of bilastine with the Menarini Group (Italy). Under the terms of the agreement, Faes has licensed bilastine rights in Europe and other regions to Menarini for the treatment of seasonal allergic rhinitis.

Bilastine is a new highly selective H1 antihistamine for once daily oral administration. Allergic rhinitis prevalence in Europe is approximately 23% and many patients are under-diagnosed and under-treated. Bilastine has been assessed in multiple human trials involving 4,000 patients, including two pivotal Phase III trials.

The agreement includes milestone payments and royalties of 10-15% of annual sales in the licensed territories, incorporating the 27 EU member states and 24 additional countries in Eastern Europe, Scandinavia, Central Asia and the Mediterranean region. The Menarini Group is a privately held company headquartered in Florence Italy with 12,000 employees and estimated 2007 turnover of euro 2,500M.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:

-- Mergers & Acquisitions

-- Strategic Partnering from preclinical research to product development

and commercialization

-- Spin-Outs and Divestitures

-- Financing (Private Placements)

-- Advisory Services to define the role of transactions in achieving

strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. The company's 60 person scientific and business team, supported by its 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life sciences companies and management, provide Burrill with unparalleled access and insight.

Burrill is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports including: The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. In association with the California Healthcare Institute, Burrill publishes The Journal of Life Sciences -- a bimonthly magazine. Burrill's flagship publication is its annual "State of the Industry" report, the most recent 21st Edition being Biotech 2007: Life Sciences - A Global Transformation. The 22nd Edition is entitled Biotech 2008: Life Sciences - A 20/20 Vision to 2020, available 1Q '08. These publications provide the latest insight, intelligence and information on the life sciences industry. http://www.burrillandco.com.


'/>"/>
SOURCE Burrill Merchant Banking
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
2. Burrill & Company Announces Promotions
3. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
4. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
8. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
9. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... more than 150 years, continues today to pursue the highest level of accuracy ... analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and ...
(Date:2/10/2016)... WASHINGTON , February 10, 2016 Early-career ... , Peru , Uganda ... their life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are ... sciences and epidemiology. They are also celebrated for mentoring young women scientists ...
(Date:2/10/2016)... York, New York (PRWEB) , ... ... ... Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human ... and immunotherapies for infectious diseases and cancer. , The Human Vaccines ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):